Compare MLGO & SCLX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | MLGO | SCLX |
|---|---|---|
| Founded | 2018 | 2011 |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | EDP Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 75.5M | 90.0M |
| IPO Year | N/A | N/A |
| Metric | MLGO | SCLX |
|---|---|---|
| Price | $5.84 | $11.37 |
| Analyst Decision | | Hold |
| Analyst Count | 0 | 1 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 190.4K | 75.9K |
| Earning Date | 03-27-2026 | 11-14-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 4.04 | N/A |
| Revenue | ★ $61,302,336.00 | $40,360,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $749.70 |
| P/E Ratio | $1.42 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $4.30 | $3.60 |
| 52 Week High | $972.00 | $34.27 |
| Indicator | MLGO | SCLX |
|---|---|---|
| Relative Strength Index (RSI) | 48.17 | 31.18 |
| Support Level | $5.19 | $11.10 |
| Resistance Level | $6.38 | $13.83 |
| Average True Range (ATR) | 0.52 | 0.99 |
| MACD | 0.13 | -0.02 |
| Stochastic Oscillator | 69.80 | 8.28 |
MicroAlgo Inc is divided into two segments: Central processing algorithm services & Intelligent chips and services. The majority is from the Central Processing Algorithm Services. which refers to a range of computing algorithms, analytical algorithms, recommendation algorithms, & acceleration algorithms. The businesses engaged in internet advertisement, game development, intelligent chip design, finance, retail, & logistics depend on the ability to process & analyze data with optimized computing software & hardware capable of handling the data workload. Intelligent chips and services revenues include revenues generated from the resale of intelligent chips. All of the Company's net revenues were generated in the PRC, Hong Kong, & Singapore, out of which the majority is from the PRC.
Scilex Holding Co is focused on acquiring, developing, and commercializing non-opioid pain management products for the treatment of acute and chronic pain. The Company's commercial product, ZTlido (lidocaine topical system), is a prescription lidocaine topical product for relieving pain associated with postherpetic neuralgia, which is a form of post-shingles nerve pain. It is focused on commercializing Gloperba (colchicine USP) an oral solution, a prophylactic treatment for painful gout flares in adults. The Company's three product candidates are SP-102 or SEMDEXA viscous gel formulation of a used corticosteroid for epidural injections, SP-103 a Phase 2, triple-strength formulation of ZTlido, and SP-104, 4.5 mg Delayed Burst Release Low Dose Naltrexone Hydrochloride (DBR-LDN) Capsule.